Glioma Treatment Market Report 2026

Glioma Treatment Market Overview

• Glioma Treatment market size has reached to $5.37 billion in 2025 • Expected to grow to $7.44 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Glioma Treatment Market Driven By The Surge In Demand For Personalized Medicine • Market Trend: Advancement In Glioma Treatment The Launch Of Vorasidenib • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Glioma Treatment Market?

Glioma treatment refers to a treatment that reduces symptoms, removes and control the tumor and limits long-term damage to the brain or spinal cord. They are used to kills any glioma cells that might remain after surgery. The main glioma treatment types are low-grade, and high-grade. Low-grade gliomas refer to tumors that develop in the brain and have a tendency to slow growth. The various diseases are glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and others with various route of administrations that includes oral, parenteral, and others can be treated by various surgeries that are radiation therapy, chemotherapy, targeted drug therapy, and others. The end users are hospitals, specialty clinics, and others.

What Is The Glioma Treatment Market Growth Forecast?

The glioma treatment market size is expected to see strong growth in the next few years. It will grow to $7.44 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to precision oncology integration, development of novel targeted drugs, improved survival outcome focus, expansion of specialty oncology clinics, personalized treatment protocols. Major trends in the forecast period include increased use of combination therapy approaches, rising focus on early surgical intervention, expansion of targeted drug therapies, growing role of radiation therapy optimization, improved long-term disease management.

What Is The Driver Of The Glioma Treatment Market?

The growing demand for personalized medicine is expected to propel the growth of the glioma treatment market going forward. Personalized medicine refers to a customized healthcare approach that takes into account individual patient traits, including genetics, environment, and lifestyle, to enhance treatment effectiveness and outcomes. The increasing demand for personalized medicine is driven by several factors, including advancements in genomics, patient empowerment, and improved treatment efficacy. The identification of biomarkers linked to gliomas helps predict treatment responses and outcomes, enabling the development of personalized treatment plans tailored to the unique characteristics of each patient. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine drives the growth of glioma treatment industry.

Key Players In The Global Glioma Treatment Market

Major companies operating in the glioma treatment market are Merck & Co Inc., Amgen Inc., F Hoffmann-La Roche AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Bristol-Myers Squibb Co., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Emcure Pharmaceuticals Ltd., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bayer AG, Gilead Sciences Inc., Ipsen Pharma, Eisai Co. Ltd., Genentech Inc., Iovance Biotherapeutics Inc., Agios Pharmaceuticals Inc.

Global Glioma Treatment Market Trends and Insights

Major companies operating in the glioma treatment market are adopting new innovative products such as immunotherapies to improve patient outcomes and target tumors more effectively. Immunotherapies are treatments that stimulate or harness the body’s immune system to recognize and attack cancer cells. For instance, in June 2024, Servier Pharmaceuticals, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets, marking a significant milestone as the first targeted therapy for Grade 2 IDH-mutant glioma. Vorasidenib is a dual inhibitor targeting isocitrate dehydrogenase (IDH) 1 and 2 mutations, which are commonly found in gliomas. These mutations lead to the production of 2-hydroxyglutarate (2-HG), a metabolite that promotes tumor growth and survival. By inhibiting these enzymes, vorasidenib reduces 2-HG levels, thereby potentially slowing tumor progression.

What Are Latest Mergers And Acquisitions In The Glioma Treatment Market?

In February 2023, Kite, a US-based global biopharmaceutical company, acquired Tmunity Therapeutics for an undisclosed amount. This acquisition broadens, diversifies, and enhances Kite's internal capabilities for cell therapy research by adding more pipeline assets. It will provide Kite access to pre-clinical and clinical programs, including an 'armored' CAR T technology platform that might be used to improve the anti-tumor activity of several CAR-Ts. Tmunity Therapeutics Inc. is a US-based biotherapeutics company developing novel products to unleash diffuse intrinsic pontine glioma treatment.

What Defines the Glioma Treatment Market?

The glioma treatment market includes revenues earned by entities by cerebral spinal fluid diversion, internal radiation therapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glioma Treatment Market Report 2026?

The glioma treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glioma treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.